Trials / Completed
CompletedNCT04278248
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
A Randomized, Blinded, Parallel Controlled, Phase Ⅲ Clinical Trial to Evaluate Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,940 (actual)
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 23-Valent Pneumococcal Polysaccharide Vaccine | 1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine. |
Timeline
- Start date
- 2018-01-12
- Primary completion
- 2018-06-07
- Completion
- 2018-06-07
- First posted
- 2020-02-20
- Last updated
- 2020-02-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04278248. Inclusion in this directory is not an endorsement.